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The data from these focus groups should be viewed in light that the 
patients participating were all well enough to do so. Needs of people 
with more advanced disease (and their carers) may be different. 
Conclusions: This study contributes to increased understandings of the 
patient experience, and that of informal carers, to assist in the provision 
of information for decision making and in supporting patients in coping 
with NSCLC. These ﬁndings will also contribute to understandings 
of the experiences of NSCLC patients and carers, compared to those 
with other cancers. Care should be taken in ensuring that people with 
NSCLC do not “fall through the cracks” of treatment services and are 
able to ﬁnd the support they require. 
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Pharmacoeconomic analysis shows that erlotinib is cost-saving 
versus docetaxel, and cost-effective versus best supportive care 
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Background: Erlotinib is a potent, orally active inhibitor of EGFR 
tyrosine-kinase activity. In a randomised, phase III study (BR.21), erlo-
tinib was shown to signiﬁcantly prolong survival, delay symptom pro-
gression and improve quality of life compared with placebo in patients 
with relapsed NSCLC (Shepherd et al. NEJM 2005;353:123-32; Bezjak 
et al. JCO 2006;24:3831-7). The improvement in survival with erlotinib 
did not depend on tumour EGFR expression status. Using efﬁcacy data 
from the overall BR.21 population, combined with local health care 
utilisation data, we conducted a pharmacoeconomic analysis of erlo-
tinib in 2nd/3rd-line treatment of NSCLC in the Netherlands.
Methods: Two economic analyses were performed, one comparing er-
lotinib with docetaxel and the other with BSC. Efﬁcacy was expressed 
as life-years gained (LYG) and was calculated for erlotinib and BSC 
from the BR.21 intent-to-treat population. No head-to-head data are 
available for erlotinib and docetaxel, but clinical evidence suggests 
similar efﬁcacy (Ramalingam and Sandler, Oncologist 2006;11:655-
65). We therefore assumed LYG for docetaxel to be equal to that for 
erlotinib. LYG were extrapolated to 3 years following start of treatment 
to capture the survival data for all patients. Cost components were: 
frequency and duration of hospitalisation; outpatient consultations; 
radiotherapy; treatment of side effects; diagnostic procedures and labo-
ratory tests; drug use; and drug administration procedures. Dutch health 
care utilisation (HCU) data for patients with relapsed NSCLC were 
obtained by retrospective chart review (n=96). Twenty-four charts were 
analysed for patients treated with docetaxel, and 72 for those receiv-
ing BSC, from 4 general hospitals and 1 academic hospital. All prices 
were taken from 2004; except the erlotinib price (2005). Both cost and 
efﬁcacy results were discounted at 4%. Pharmacoeconomic analysis 
was performed with a Markov health-state model, using a base case and 
alternative scenarios. HCU data and model assumptions were approved 
by an expert panel of 10 Dutch lung cancer specialists.
Results: The average cost of treatment was €24,939 for docetaxel-
treated patients, compared with €23,436 for erlotinib-treated patients 
and €15,450 for patients on BSC. LYG were 0.84 years for docetaxel 
and erlotinib, and 0.62 years for BSC. Erlotinib was found to be cost 
saving versus docetaxel in most scenarios, except when assuming an 
unrealistically low dose of docetaxel (110mg/cycle). The incremental 
cost-effectiveness ratio (ICER) for erlotinib versus BSC was €37,551 
per LYG (CI €12,621-€72,960), based on an average treatment dura-
tion of 4.3 months. ICERs were sensitive to variations in the length and 
frequency of hospitalisation, as well as the number of outpatient con-
sultations. Assuming a willingness-to-pay (WTP) threshold of €50,000 
per LYG, and using the conﬁdence intervals of a select number of 
variables, erlotinib was found to be cost-effective compared with BSC 
in 80% of cases.
Conclusions: In patients with relapsed NSCLC, treatment with erlo-
tinib was found to be cost-saving versus docetaxel and cost-effective 
versus BSC. Based on the combined ﬁndings of clinical efﬁcacy and 
cost-effectiveness, erlotinib received unrestricted reimbursement in the 
Netherlands for patients with relapsed NSCLC.
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A phase 3 randomized, double blind, placebo-controlled study of 
patients with previously untreated extensive-stage small cell lung 
cancer (SCLC) treated with platinum plus etoposide chemotherapy 
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Background: Erythropoiesis-stimulating agents are widely used for the 
treatment of chemotherapy-induced anemia. Here we present results of 
a trial that evaluated the effect of darbepoetin alfa (DA) versus placebo 
on hemoglobin (Hb) concentration, survival, and disease progression in 
anemic cancer patients with previously untreated extensive-stage SCLC.
Methods: Patients with extensive-stage SCLC (n=597), ≥18-years old, 
and baseline Hb ≥9g/dL and ≤13g/dL, were randomly allocated 1:1 
DA:placebo. Randomization was stratiﬁed by region (Western Europe; 
Australia/North America; rest of world), performance status (0-1 versus 
2), and LDH (normal versus abnormal). DA 300µg or placebo was 
administered once per week (QW) for 4 weeks, then every 3 weeks 
(Q3W) until end of treatment. The dose was withheld if Hb increased 
≥14g/dL and resumed QW (weeks 1-4) or Q3W (week 5 to end of treat-
ment) once Hb dropped <13g/dL. Administration of study drug began 
with the ﬁrst cycle of on-study chemotherapy (cisplatin or carboplatin 
plus etoposide Q3W), continuing throughout 6 cycles. End-of-che-
motherapy period (EOCP) visits occurred up to 3 weeks after the last 
chemotherapy dose, and end-of-study treatment (EOST) visits occurred 
8 weeks after completion of chemotherapy; follow-up visits occurred 
every 3 months until death. Co-primary endpoints were mean change 
in Hb concentration during chemotherapy and survival. A prespeciﬁed 
